Page last updated: 2024-12-10
metoxibutropate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 4464271 |
| CHEMBL ID | 4795894 |
| CHEBI ID | 135336 |
| SCHEMBL ID | 5080304 |
| MeSH ID | M0073663 |
Synonyms (34)
| Synonym |
|---|
| metoxibutropate |
| af-2259 |
| flubenil |
| benflogin |
| ibuprofen guaiacol ester |
| methoxybutropate |
| 2-methoxyphenyl 2-(4-isobutylphenyl)propionate |
| guaiacol 4-isobutylhydratropate |
| benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-, 2-methoxyphenyl ester |
| 2-methoxyphenyl alpha-methyl-4-(isobutyl)phenylacetate |
| brn 2664678 |
| propionic acid, 2-(p-isobutylphenyl)-, o-methoxyphenyl ester |
| einecs 266-318-9 |
| alpha-methyl-4-(2-methylpropyl)benzeneacetic acid 2-methoxyphenyl ester |
| 2-(p-isobutylphenyl)propionic acid o-methoxyphenyl ester |
| af 2259 |
| CHEBI:135336 |
| 66332-77-2 |
| benflogin (tn) |
| D08213 |
| (2-methoxyphenyl) 2-[4-(2-methylpropyl)phenyl]propanoate |
| unii-0n623mnk8z |
| 0n623mnk8z , |
| SCHEMBL5080304 |
| ibuprofen guaiacol ester [who-dd] |
| AKOS027379916 |
| 2-methoxyphenyl 2-[4-(2-methylpropyl)phenyl]propanoate |
| DTXSID10984948 |
| CHEMBL4795894 |
| af 2259; methoxybutropate; metoxibutropate |
| Q27236986 |
| EN300-18567259 |
| Z3244866822 |
| 2-methoxyphenyl2-(4-isobutylphenyl)propanoate |
Research Excerpts
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "metoxibutropate) are able to inhibit in-vitro prostaglandin synthesis." | ( Effects of metoxibutropate, ibuprofen and guaiacol on the gastrointestinal system. Bandi, GL; Bozzi, M; Formenti, A; Fossati, A; Passarotti, C; Vimercati, MG, 1991) | 1.39 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The semialkaline proteolithic enzyme Seaprose S, available in 30 mg tablets was administered at a dosage of 3 tablets a day for a period of 8 days." | ( [Clinical effectiveness and safety of Seaprose S in the treatment of complications of puerperal surgical wounds]. Candotti, G; Dindelli, M; Frigerio, L; Pifarotti, G; Potenza, MT, ) | 0.13 |
| " Oral granules of nimesulide were administered in daily dosage of 200 mg." | ( [Controlled clinical study of the efficacy and tolerability of methoxybutropate compared to nimesulide in gynecology]. Ajossa, S; Guerriero, S; Mais, V; Melis, GB; Paoletti, AM, 1997) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| monoterpenoid | Any terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.08
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.08) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (35.71%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||